Articles On Zelda Therapeutics (ASX:ZLD)

Emerging Companies (XEC) index dives 2.6% Benchmark ASX200 down 0.6% Culpeo Minerals meets copper, shares up 70%   Aussie small caps have copped a commodities shellacking to start the week as materials, metals and energy stocks bear the...

A Thai university says adding cannabis to chicken feed has positive results on meat and egg quality Aussie cannabis campaigner now a Member of the Order of Australia MGC Pharma’s CBD treatment proves effective against brain tumors   Chian...

Zelira Therapeutic’s (ZLD) share price is on the rise after releasing results of its study on its ZENIVOL drug as a therapeutic option to manage chronic insomnia symptoms In a white paper published by Zelira in collaboration with Emyria (E...

ASX set to open higher today despite rising rate risks Tech leads Wall Street overnight Goldman predicts US$140 oil price Local shares are set to bounce back from yesterday’s 1.53% fall, with the ASX 200 June futures pointing up by 0.60%...

Over the past decade, opioid-induced deaths were more likely to be due to prescription drugs than illegal drugs As scientists discover new ways to use the plant’s medicinal compounds, cannabis is seen as a possible solution to the opioid c...

Zelira Therapeutics (ZLD) completes enrolment for its diabetic nerve pain drug trial The trial will evaluate the efficacy and tolerability of Zelira’s proprietary medicinal cannabis product against an undisclosed multi-billion-dollar “big...

Invion demonstrates high efficacy of INV043 when used as a combined therapy Biotron gets positive feedback from US FDA Biome stocks its Probiotics range on Priceline’s shelves Invion demonstrates efficacy Cancer fighter Invion (ASX:IVX) w...

Actor Woody Harrelson has opened a cannabis store in West Hollywood Releaf has plans for a weed wellness retreat in Byron Bay Incannex wants to buy out APIRx   It’s not surprising that Woody Harrelson loves weed – the actor was actually...

Nyrada’s European patent submission gets a patent number Zelira’s positive study results on its autism tincture, HOPE  Beamtree gives beaming trading update Cardiovascular and neurological diseases fighter, Nyrada (ASX: NYR), says the Eur...

ASX to open higher as Wall Street returns a mixed bag Oil prices are higher by 3% El Salvador to host a Bitcoin summit with 44 other countries/institutions Aussie shares are set to open higher this morning, despite a mixed bag of results...

US Seed Connect launched Cannabis Crypto Seed Headz NFT Washington launches week-long cannabis tax holiday Medlab clinical makes moves in the Northern Hemisphere with manufacturing deal Wednesday was 4/20 day – while it’s more of an unoff...

Zelira Therapeutics (ASX:ZLD) has announced it has executed a binding scheme implementation deed under which it proposes to acquire 100 per cent of Health House.

Hemp farmers in New York have been given the go ahead to plant cannabis for the 2022 season. The legislation allows conditionally licensed cannabis farmers to grow weed, but they must meet certain requirements, including safe, sustainable a...

At the time of writing, the ASX 200 Health Index (XHJ) is down by 1.10%, while the benchmark ASX 200 has fallen by 2.15%. It’s all about earnings today for ASX health stocks. Here’s a highlight of where they stand in the first half.   Round...

Zelira Therapeutics (ZLD) is set to take over Health House International to expand the market reach of its medicinal cannabis products Under the scheme, Zelira will issue shares to Health House parties at 19.45 per cent interest in the exp...

Zelira Therapeutics (ASX:ZLD), a company focused on the development of clinically validated cannabis medicines, has appointed Tim Slate as a non-executive director.

Immuron nabs $6.2m clinical research deal for US Military strength Travelan dose ECS Botanics reports record revenue of $1.5m expected for Q2 FY22 Compumedics secures first major magnetoencephalography (MEG) sale in China Immuron (ASX:IMC...

Zelira Therapeutics (ZLD) has received a $1.29 million cash refund under the Federal Government’s research and development tax incentive scheme. The cash was part of a program under which companies receive refunds for eligible expenditure...

Zelira Therapeutics (ZLD) has received US$250,000 (A$348,000) for its technology which enables the enhanced dissolution of cannabinoids The company expects to receive the full US$1 million upfront, non-refundable, non-contingent licence pa...

Zelira Therapeutics (ZLD) expands into the New Zealand cannabinoid-based medicines market via a five year exclusive distribution agreement with NUBU Pharmaceuticals The deal allows Zelira to market its Zenivol and Hope 1 products in New Ze...

The ASX 200 Health Index (XHJ) has dropped by almost 5% at the time of writing, compared to the broader index which is down by 0.20%. Healthcare giant and blood specialist, CSL (ASX:CSL), which makes up a large part of the ASX Healthcare in...

Wall Street rallies on Fed decision US stocks rallied strongly overnight, as investors digested the central bank’s decision to speed up its tapering program and hike rates next year. Fed Reserve governor Jerome Powell said the bank will red...

Zelira Therapeutics (ASX:ZLD) has announced ethics approval has been granted for the Phase 2a clinical trial of its cannabinoid formulation, ZTL-106, in treating patients with chronic pain.

Zelira Therapeutics (ZLD) receives ethics approval for its Phase 2a clinical trial for chronic pain As part of its licensing and project management with Levin Health, the study will evaluate the efficacy of Zelira’s cannabinoid formulation...

Zelira Therapeutics (ZLD) signs a licensing deal for its Enhanced Distillate Capture and Dissolution Matrix (EDCDM) technology DRCN Holding will pay a US$1 million (A$1.35 million) licensing fee for the tech and has three years to develop...

Fresh record highs on Wall Street ahead of Fed statement US stocks continued their strong recent run overnight, and finished at fresh record levels for the third day in a row. All three benchmarks indexes rose – the Dow Jones rose by 0.39%,...

As the world emerges from the pandemic, markets are now contending with an energy crisis, a global shipping glut and the prospect of central banks starting to raise interest rates. But so far this week, investors are shrugging it all off as...

Zelira Therapeutics (ZLD) raises US$5 million (around A$6.69) from US family office fund, Quincy Street Capital Quincy Street has now become a substantial shareholder in Zelira with a 6.3 per cent stake Funds from the raise will be used to...

Just like yesterday the ASX rallied for most of the day but retreated in the afternoon and today closed in the red. The ASX 200 was down 0.08% at 7,375 points. Another difference from yesterday was tech was the best sector gaining 1.7% whil...

Zelira Therapeutics (ZLD) calls a two-day trading halt as it gears up to raise some fresh funds The company is yet to announce how much it plans to raise or for what it will use the funding boost Taking a look at Zelira’s latest financial...

Retail giant Amazon has rejigged its cannabis policy, allowing employees who were previously fired for testing positive for marijuana to reapply for jobs. The company has now excluded marijuana from its comprehensive pre-employment drug scr...

Wall Street higher as US Fed firms up November tapering US stock markets were higher overnight, as US Fed Chairman Jerome Powell signalled the bank would start tapering its asset purchases starting in November, which would last until the mi...

Wall Street slips as iron ore falls further All three US stock market indexes fell on Friday, ahead of the US Fed rates decision this Wednesday (US time). The Dow Jones fell by 0.48%, S&P500 by 0.91%, and the tech heavy Nasdaq also fell...

ShareCafeHidden Gems Webinar Recap – ZLD, WTL, AGN, CLA Catch up on the full webinar with presentations from  Zelira Therapeutics (ASX: ZLD), Argenica Therapeutics (ASX:AGN), WT Financial Group (ASX: WTL) & Celsius Resources Limited (...

Wall Street at fresh record highs All three key US benchmarks rose and reached fresh record highs on Friday, ahead of kick-off in earnings season. The Dow Jones was up by 1.30%, S&P 500 by 1.13%, and tech heavy Nasdaq by 0.98%. Bank sto...

The 2021 financial year was overall a very good one for ASX shares. The S&P/ASX 200 Index (ASX: XJO) managed to put on a performance of 24% for the 12 months to 30 June 2021. That makes FY2021 one of the best financial years ever for t...

Cannabis stocks have welcomed the change in ownership of Pershing Australia from Bank of New York Mellon (BNYM) to Finclear Pty Ltd which – effective immediately – will allow the trading of cannabis securities on the ASX. In late 2019, BNYM...

Connecticut has become the latest US state to legalise recreational use of marijuana. The state’s governor has just signed a bill to allow people aged 21 and older to possess and consume marijuana, making it the 19th US state to do so. Here...

The US cannabis sector received a big lift after Amazon announced that job applicants at its offices and warehouses will no longer be drug-tested for marijuana use. Delivery drivers, however, will still be tested. The company also said it w...

The ASX 200 just closed 0.92 per cent up at 7,380 points  —  a new record high. The ASX Emerging Companies Index however fell 1.66 per cent, closing at 2,180. The best sector on the ASX was health which gained over 2 per cent while consumer...

Wall Street mixed ahead as Nasdaq hits record highs Major indices in the US were mixed on Monday, with tech stocks leading the way, ahead of Thursday’s US Fed key policy meeting. The Dow Jones fell by 0.25%, S&P 500 rose by 0.18%, and t...

The medicinal cannabis industry is gaining significant momentum, however, still remains in the early stages of growth. Zelira Therapeutics recently reported record quarterly cash receipts for the third quarter, up 249 per cent on H1 FY21. F...

Summary Hillgrove Resources’ share price has skyrocketed 64.8% today and is currently trading at AU$0.089. Today, Veris’ share has given a breakout from a consolidation phase on the chart. The Red Sky Energy share price is also runnin...

Summary Diagnostics company Rhythm Biosciences has confirmed that LRF enhancements have shown to improve ColoSTAT® results. Cannabis medicines developer Zelira Therapeutics has entered into a partnership with Alternative Solutions for...

The Zelira Therapeutics Ltd (ASX: ZLD) share price is firmly in the green today following a positive update for its HOPE products. At the time of writing, the cannabis company’s shares are swapping hands for 5.7 cents, up 7.55%. What did Z...

Dow Jones at record level, as US tech stocks sell off again The Dow Jones index has reached its all-time high, rising by 0.29% to finish at a record 34,230. However, tech stocks sold off again, with the likes of Amazon and Facebook falling...

Summary ASX-listed Splitit Payments Limited announced strong growth in Merchant Sales Volume (MSV) and revenue in Q1 FY2021. The Company’s brand awareness increased during the quarter, evident by the 70K increase in new shoppers. The...

The Zelira Therapeutics Ltd (ASX: ZLD) share price is lower during mid-afternoon trade despite announcing a positive trading update. At the time of writing, the cannabis company’s shares are fetching for 5.9 cents, down 1.67%. Q3 FY21 quar...

Zelira Therapeutics (ASX:ZLD) says it generated record quarterly product sales and licensing revenues of $225,000 for the March 2021 quarter, up 249 per cent from the previous six months.

Wall Street mixed, even as banks’ earnings beat estimates US investors took the strong banks’ earnings in stride, with the major US indices petering out to a mixed finish. Major banks Goldman Sachs, JP Morgan and Wells Fargo unveiled quarte...